PathAI

PathAI (IPA: ) is a biomedical software company focused on using artificial intelligence in pathology based in Boston, Massachusetts, United States. Competitor companies currently include Deep Lens, Inspirata, and Proscia.
History
PathAI was founded by co-founders Andrew H. Beck and Aditya Khosla with the goal of reducing "error rates, increase accuracy and reproducibility" in pathology. In 2017, the company began partnering with pharmaceutical companies to work on drug development. In 2021, with $165M raised in Series C funding (co-led by D1 Capital Partners and Kaiser Permanente) the company began clinical diagnostics with the acquisition of Poplar, a lab service provider for Poplar Healthcare PLLC. Since then, several industry collaborations have been established with companies such as Roche, LabCorp, and Cleveland Clinic.
Sponsors currently include:
Products and Services
PathAI initially focused on applications in drug development but expanded to the clinical setting in 2021. Currently, their main focuses are:
Translational Research
Translational research is the conventional method of research in which pathologists and data scientists apply existing and new models to process samples. Samples may be interpreted from off-site labs or analyzed on-site. This method of research focuses to "identify new insights on pharmacodynamics, mechanism of action, and patient stratification".
Clinical Trial Services
Clinical trial services is a method of analysis used to help identify biomarkers for "patient enrollment, endpoint analysis, and correlative studies in prospective clinical trials".
* A CD8 classifier paired with PD-L1 status increased biomarker-positive patients 40% over prior PD-L1 studies.
* A PD-L1 model which identified 28% additional positive patients from a retrospective analysis on false negatives.
* A model which predicted HRD status from H&E-stained slides. brought light to the fact.
Refeences

Main Menu

See Also

Main Menu